Collaboration and license agreements (Tables)

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of allocation of transaction price

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of March 31, 2023 (in thousands):

	Transaction Price Allocated		Transaction Price Unsatisfied
Performance obligations:
Research and development targets	$	61,074	$	25,189
Option rights	6,748		2,502
Total	$	67,822	$	27,691

Schedule of revenue from collaboration agreements

Revenue from collaboration agreements for the three months ended March 31, 2023 and 2022 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Revenue from collaboration agreements:
Roche Agreement	$	353	$	1,123
Biogen Agreement	2,336		4,716
Calico Agreement	1,070		1,815
Total revenue from collaboration agreements	$	3,759	$	7,654

Schedule of financial information related to collaboration and license agreements

Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of March 31, 2023 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	—	$	5,847	$	15,845	$	21,692
Biogen Agreement	—		9,090		—		9,090
Calico Agreement	528		—		—		—
Total	$	528	$	14,937	$	15,845	$	30,782

Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2022 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	417	$	4,649	$	16,895	$	21,544
Biogen Agreement	—		11,427		—		11,427
Calico Agreement	1,056		542		—		542
Total	$	1,473	$	16,618	$	16,895	$	33,513

Schedule of supplemental financial information related to collaboration and license agreements

Supplemental financial information related to the collaboration and license agreements for the three months ended March 31, 2023 and 2022 are (in thousands):

	Three Months Ended March 31,
	2023		2022
Revenue recognized that was included in the contract liability at the beginning of the period	$	3,231	$	6,267
Revenue recognized from performance obligations fully or partially satisfied in previous periods	$	—	$	115